TYSABRI(R) Multiple Sclerosis Clinical Trial Hold Lifted By FDA; Biogen Idec, Inc. (Massachusetts) And Elan Corporation PLC To Resume Clinical Trial Dosing In MS; Biogen Stock Rises

CAMBRIDGE, Mass. and DUBLIN, Ireland--(BUSINESS WIRE)--Feb. 15, 2006--Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc. (NYSE: ELN) announced today that the Food and Drug Administration (FDA) informed the companies that they have removed the hold on clinical trial dosing of TYSABRI(R) (natalizumab) in multiple sclerosis (MS) in the U.S. The companies expect to begin an open label, multi-center safety extension study of TYSABRI monotherapy in the U.S. and internationally in the coming weeks. Patients who previously participated in the Phase III MS program are eligible for entry.

Back to news